$37.9 M

DMAC Mkt cap, 01-Apr-2020
DiaMedica Therapeutics Net income (FY, 2019)-10.6 M
DiaMedica Therapeutics EBIT (FY, 2019)-11.6 M
DiaMedica Therapeutics Cash, 31-Dec-20193.9 M
DiaMedica Therapeutics EV34.2 M

DiaMedica Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

500.0k

R&D expense

1.7m3.2m4.5m7.9m

General and administrative expense

598.0k1.3m2.7m3.7m

Operating expense total

2.3m4.5m7.3m11.6m

EBIT

(2.3m)(4.5m)(6.8m)(11.6m)

EBIT margin, %

(1352%)

Pre tax profit

(5.7m)(10.6m)

Income tax expense

80.0k31.0k

Net Income

(2.2m)(4.3m)(5.7m)(10.6m)

Quarterly

USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

R&D expense

411.0k1.2m2.6m1.9m1.6m

General and administrative expense

415.0k777.0k814.0k867.0k1.0m

Operating expense total

826.0k2.0m3.4m2.7m2.7m

EBIT

(826.0k)(1.5m)(3.4m)(2.7m)(2.7m)

Pre tax profit

(3.2m)(2.5m)(2.4m)

Income tax expense

9.0k8.0k12.0k

Net Income

(707.0k)(1.4m)(3.3m)(2.5m)(2.4m)

DiaMedica Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.7m1.4m16.8m3.9m

Accounts Receivable

53.0k80.0k780.0k823.0k

Prepaid Expenses

67.0k61.0k369.0k47.0k

Current Assets

1.9m1.5m18.0m8.8m

PP&E

19.0k37.0k96.0k64.0k

Total Assets

1.9m1.8m18.3m9.1m

Accounts Payable

671.0k919.0k1.3m182.0k

Short-term debt

5.0k54.0k

Current Liabilities

764.0k1.0m1.3m1.3m

Long-term debt

18.0k118.0k

Non-Current Liabilities

18.0k118.0k

Total Debt

23.0k172.0k

Total Liabilities

764.0k1.0m

Common Stock

12.0m12.0m

Additional Paid-in Capital

37.1m41.0m63.0m64.2m

Retained Earnings

(36.0m)(40.2m)(46.0m)(56.6m)

Total Equity

1.1m799.0k17.0m7.6m

Financial Leverage

1.7 x2.3 x1.1 x1.2 x

Quarterly

USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

3.9m2.8m3.0m4.7m

Accounts Receivable

1.0m929.0k1.1m664.0k

Prepaid Expenses

160.0k298.0k198.0k89.0k

Current Assets

5.1m14.9m12.3m10.8m

PP&E

91.0k90.0k73.0k68.0k

Total Assets

5.5m15.5m12.8m11.0m

Accounts Payable

1.4m685.0k262.0k312.0k

Current Liabilities

1.4m1.4m947.0k1.2m

Long-term debt

163.0k148.0k134.0k

Non-Current Liabilities

163.0k148.0k134.0k

Total Debt

163.0k148.0k134.0k

Total Liabilities

1.4m

Additional Paid-in Capital

48.1m63.1m63.4m63.8m

Retained Earnings

(44.0m)(49.2m)(51.7m)(54.1m)

Total Equity

4.1m13.9m11.7m9.7m

Financial Leverage

1.3 x1.1 x1.1 x1.1 x

DiaMedica Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.2m)(4.3m)(5.7m)(10.6m)

Depreciation and Amortization

2.0k4.0k15.0k21.0k

Accounts Receivable

(44.0k)(27.0k)(700.0k)(43.0k)

Accounts Payable

(510.0k)248.0k372.0k(301.0k)

Cash From Operating Activities

(3.0m)(3.9m)(5.7m)(9.1m)

Purchases of PP&E

(7.0k)(22.0k)(50.0k)(2.0k)

Cash From Investing Activities

(7.0k)(22.0k)(50.0k)(3.9m)

Long-term Borrowings

(5.0k)

Cash From Financing Activities

4.6m3.5m21.2m70.0k

Net Change in Cash

1.6m(383.0k)15.5m(12.9m)

Interest Paid

11.0k2.0k

Income Taxes Paid

26.0k

Quarterly

USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(3.5m)(3.8m)(3.3m)(5.7m)(8.2m)

Depreciation and Amortization

2.0k10.0k6.0k11.0k16.0k

Accounts Receivable

(10.0k)(963.0k)(150.0k)(332.0k)116.0k

Accounts Payable

54.0k434.0k201.0k(221.0k)(171.0k)

Cash From Operating Activities

(2.9m)(3.8m)(3.1m)(6.0m)(7.2m)

Purchases of PP&E

(7.0k)(63.0k)

Cash From Investing Activities

(7.0k)(63.0k)(10.9m)(7.9m)(4.9m)

Long-term Borrowings

(2.0k)(3.0k)(4.0k)

Cash From Financing Activities

2.0m6.4m(2.0k)72.0k71.0k

Net Change in Cash

(905.0k)2.5m(14.1m)(13.8m)(12.1m)

DiaMedica Therapeutics Ratios

USDY, 2019

EV/EBIT

-2.9 x

EV/CFO

-3.8 x

Financial Leverage

1.2 x